azithromycin for COVID-19: living meta-analysis of clinical studies

Study explorer (study characteristics and results) method abbreviations pdf xlsx

display ongoing studies
Study	Ref.	Design	studied treatment	control treatment	patients	study risk of bias	sample sizes	Results
COVID-19 mild to moderate meta-analysis
Rashad A (AZI vs SoC)		RCT	azithromycin	standard of care	COVID-19 mild to moderate	some concern	107/99	inconclusive
COALITION I Covid-19 Brazil (AZI, Cavalcanti) NCT04322123		RCT	azithromycin	standard of care	COVID-19 mild to moderate	some concern	172/159	inconclusive	inconclusive 18 % decrease in clinical improvement,clinical improvement (14-day) (PE) with a moderate degree of certainty due to some concern in risk of bias
Espitia-Hernandez		NRa	azithromycin	standard of care	COVID 19 outpatients, COVID-19 mild to moderate	NA	28/7	uncontrolled	[uncontrolled] negative PCR on day 10: 100.0% (28/28)

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).

Study explorer (study characteristics and results) method abbreviations pdf xlsx

COVID-19 mild to moderate meta-analysis